Loomis, Sayles & Company
ICPT

Loomis, Sayles & Company’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Loomis, Sayles & Company’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-34,057
Closed -$2.33M – 785
2013
Q4 		$2.33M Buy
+34,057
New +$1.97M 0.01% 596

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Loomis, Sayles & Company's ICPT Position: Q1 2014 in Review

Loomis, Sayles & Company sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q1 2014, closing a stake of 34,057 shares — an estimated $2.33M sold.

Loomis, Sayles & Company first reported a position in ICPT in Q4 2013 and held it in 1 quarter. The position peaked at $2.33M in Q4 2013. 172 funds tracked by Wall St. Rank hold ICPT as of Q1 2014.

  • Loomis, Sayles & Company reported no remaining Intercept Pharmaceuticals, Inc. position as of Q1 2014 after selling out during the quarter.
  • Loomis, Sayles & Company sold 34,057 Intercept Pharmaceuticals, Inc. shares in Q1 2014, an estimated $2.33M.
  • Loomis, Sayles & Company first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2013 and held it in 1 quarter.
  • Loomis, Sayles & Company's Intercept Pharmaceuticals, Inc. position peaked at $2.33M in Q4 2013.
  • 172 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q1 2014.

Based on Loomis, Sayles & Company's 13F filing for Q1 2014, filed 15 May 2014.